Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today announced that management will host a conference call and webcast to discuss its first quarter 2020 financial results and other business highlights on Monday, May 4, 2020 at 9:00 a.m. ET.

Public companies in Massachusetts lost about $33 billion in market value on Monday as the markets saw the worst day in two years. The S&P 500 fell 3.4%, the worst one-day decline for the stock index since February 2018, fueled mostly by fears that the spread of coronavirus is not as well-contained as investors previously had thought. Meanwhile, the Nasdaq Composite index lost 3.7% and the Dow Jones Industrial Average shed more than 1,000 points to close the day 3.6% lower.

Epizyme (EPZM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

A week ago, Epizyme, Inc. (NASDAQ:EPZM) came out with a strong set of yearly numbers that could potentially lead to a...

Epizyme (EPZM) delivered earnings and revenue surprises of 31.08% and -48.60%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Epizyme (EPZM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today provided business and pipeline updates and reported first quarter 2020 financial results.

Allogene (ALLO) reports no revenues for the first quarter of 2020.

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Bob Bazemore became the CEO of Epizyme, Inc. (NASDAQ:EPZM) in 2015. This report will, first, examine the CEO...

Q1 2020 Epizyme Inc Earnings Call

Epizyme (EPZM) reports wider-than-expected loss in the fourth quarter of 2019. Nonetheless, its sales beat estimates.

Shares of Epizyme (NASDAQ:EPZM) were unaffected at $15.75 after the company reported Q1 results.Quarterly Results Earnings per share fell 30.77% over the past year to ($0.51), which beat the estimate of ($0.74).Revenue of $1,354,000 less by 82.84% from the same period last year, which missed the estimate of $3,680,000.Guidance Epizyme hasn't issued any earnings guidance for the time being.Epizyme hasn't issued any revenue guidance for the time being.How To Listen To The Conference Call Date: May 04, 2020View more earnings on EPZMTime: 03:04 AM ETWebcast URL: https://edge.media-server.com/mmc/p/shejfym8Price Action Company's 52-week high was at $27.82Company's 52-week low was at $9.73Price action over last quarter: down 26.71%Company Profile Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing & commercializing novel epigenetic medicines. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL), Phase II clinical trial for relapsed or refractory patients with mesothelioma, Phase I dose-escalation and expansion study for children with INI1-negative solid tumors. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias & PRMT5 inhibitor.See more from Benzinga * Stocks That Hit 52-Week Lows On Friday * Price Over Earnings Overview: Michaels Companies * Morning Market Stats in 5 Minutes(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Investors need to pay close attention to Epizyme (EPZM) stock based on the movements in the options market lately.

On the call with me is Rob Bazemore, CEO; Matt Ros, Chief Strategy and Business Officer; Dr. Shefali Agarwal, Chief Medical Officer; and Paolo Tombesi, Chief Financial Officer who will join us for the Q&A session. This approval made TAZVERIK the first and only FDA-approved treatment specifically indicated for epithelioid sarcoma patients and the first and only approved EZH2 inhibitor on the market.

Epizyme Appoints Jeffery Kutok, M.D., Ph.D., as Chief Scientific Officer

Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]

Epizyme to Present Data from Tazemetostat Clinical Program during the 2020 ASCO Virtual Scientific Program

Q4 2019 Epizyme Inc Earnings Call

Epizyme (EPZM) reports a narrower-than-expected Q1 loss but misses on revenues.